2 ASX Healthcare Shares Making Splashes in the US
Euroz Hartleys Upgrades Botanix Pharmaceuticals' to Buy From Speculative Buy, Adjusts Price Target to AU$0.47 From AU$0.33
AU Evening Wrap: ASX 200 Rises 0.3%, Ends Week Up 0.9%
Botanix Pharmaceuticals to Raise AU$70 Million via Institutional Placement
Botanix Pharmaceuticals Secures US FDA Approval for Topical Medication
Botanix Pharmaceuticals Share Price on Watch Amid FDA News and 'Transformative Event'
Botanix Isn't Sweating on FDA Approval for Sofdra
Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target
Euroz Hartleys Adjusts Botanix Pharmaceutical's Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy
Botanix Pharmaceuticals Price Target Raised 10% to A$0.33/Share by Euroz Hartleys
We're Keeping An Eye On Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
Botanix Pharmaceuticals Price Target Raised 12% to A$0.19/Share by Petra Capital
If You'd Put $40,000 in This ASX Healthcare Stock at the Start of 2023, You'd Have $128,000 Now
US FDA Accepts Resubmission of Botanix Pharmaceuticals' Topical Medication
Botanix Pharmaceuticals Completes US FDA Resubmission for Topical Medication; Shares Gain 3%
Botanix Pharmaceuticals Completes Human Factors Validation Study for Topical Medication; Shares Rise 3%
Botanix Pharmaceuticals Initiated at Hold by Petra Capital
Botanix Pharmaceuticals Secures US FDA Feedback for Topical Medication
Botanix Pharmaceuticals Completes Nearly AU$14 Million Institutional Placement
Botanix Pharmaceuticals Price Target Cut 3.2% to A$0.30/Share by Euroz Hartleys
No Data